search
Back to results

Non-invasive Therapy to Drive Nerve Regeneration

Primary Purpose

Peripheral Nerve Injuries

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Acute Intermittent Hypoxia
Normoxia
Sponsored by
University of Alberta
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Nerve Injuries

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: i) sensory impairments including numbness and pain; ii) nocturnal awakening by these symptoms; iii) weakness and wasting of the thenar musculature and, iv) loss of hand dexterity. v) Motor unit loss greater than 2 SD below the mean for the age group Exclusion Criteria: i) Chronic lung or cardiac disease ii) Other nerve disorders, previous carpal tunnel release or systemic illness including diabetes

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Acute Intermittent Hypoxia

    Normoxia control

    Arm Description

    Patients with hand weakness and numbness secondary to median nerve entrapment and scheduled for carpal tunnel release surgery will be randomly assigned to receive acute intermittent hypoxia

    Patients with hand weakness and numbness secondary to median nerve entrapment and scheduled for carpal tunnel release surgery will be randomly assigned to receive normoxia

    Outcomes

    Primary Outcome Measures

    Motor unit number estimation
    The number of motor units in the median innervated thenar muscles.

    Secondary Outcome Measures

    Two point discrimination
    Testing the A-beta sensory fibers using the Dellon-MacKinnon Disk
    Fine touch sensation
    Testing the A-beta fibers using Semmes-Weinstein monofilaments
    Quantitative sensory testing
    Cold threshold (A-beta fibers) and pain threshold (C fibers) using CASE IV quantitative sensory testing equipment
    Boston Carpal Tunnel Symptom Severity
    Self administered questionnaire
    Moberg Pick-up Test
    To measure hand dexterity and functional performance

    Full Information

    First Posted
    April 5, 2023
    Last Updated
    July 28, 2023
    Sponsor
    University of Alberta
    Collaborators
    Canadian Institutes of Health Research (CIHR), Royal Alexandra Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05848778
    Brief Title
    Non-invasive Therapy to Drive Nerve Regeneration
    Official Title
    Novel Non-invasive Therapy to Drive Robust and Sustained Peripheral Nerve Regeneration
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 1, 2023 (Anticipated)
    Primary Completion Date
    August 31, 2027 (Anticipated)
    Study Completion Date
    August 31, 2028 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Alberta
    Collaborators
    Canadian Institutes of Health Research (CIHR), Royal Alexandra Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Peripheral nerve injuries are common and often associated with poor outcomes including incomplete repair, debilitating pain states and compromised function. Although nerve regeneration can be enhanced by brief electrical nerve stimulation at the time of or before surgical repair in rodents and humans, this approach is invasive. Acute intermittent hypoxia, breathing alternate cycles of regular air and air with ~50% normal oxygen levels (11% O2) is an emerging, promising non-invasive therapy promoting respiratory and non-respiratory muscle function in spinal cord injured rats and humans. Because the entire body is exposed to this therapy, it has the potential to globally impact the nervous system beyond just controlling respiratory and leg function in spinal cord injured patients. Thus, the investigators hypothesized that an acute intermittent hypoxia paradigm similar to that used for spinal cord repair will improve peripheral nerve repair in a manner akin to electrical stimulation, including its impact on expression of regeneration-associated proteins - a predictor of nerve growth states. In recent studies the investigators found this to be the case and now propose to continue these promising studies by performing a pilot clinical trial evaluating this form of treatment on patients with compromised hand function due to severe carpal tunnel syndrome. The goal is to improve nerve repair outcomes in the least invasive and optimal manner.
    Detailed Description
    Peripheral nerve injuries are frequent and disabling, often with irreversible consequences. Injured sensory and motor neurons induce cellular and molecular events we refer to as the intrinsic repair program, linked to their regeneration capacity. Regrettably, regeneration of these nerves is challenging. Issues include whether the intrinsic repair program is robust enough, or is sustained long enough, to ensure repair over long distances. This can result in incomplete repair and/or pain states. The investigators will exploit acute intermittent hypoxia (intermittent periods of reduced oxygen), a novel treatment to condition/prime peripheral nerves and induce an enhanced intrinsic repair program. Acute intermittent hypoxia is non-invasive and has a systemic effect which is a major advantage in cases where there are multiple nerve injured in a widespread distribution, as opposed to electrical stimulation that only impacts the individual nerve stimulated. However, the full potential of acute intermittent hypoxia in nerve repair remains unknown. This will be a Phase I randomized control trial of carpal tunnel syndrome associated with severe median nerve compression/injury. This is designed to test the hypothesis that acute intermittent hypoxia before and/or after nerve decompression will result in more effective nerve regeneration and restoration of function. Methods: Using a double blinded randomized controlled trial design, we will recruit 80 adult patients (50% male; 50% female) >18 yrs old with severe carpal tunnel syndrome. Statistical analysis: Distribution of the outcome data will be analyzed using the Shapiro-Wilk test. For parameters that are normally distributed, differences between the groups will be compared using 2-way analysis of variance (ANOVA) with time and treatment allocation being the independent factors. When a statistically significant difference (p<0.05) is found, post hoc testing will be done using the Tukey test. For data that is not normally distribution, the Kruskal-Wallis test will be used instead, followed by post hoc analysis with Dunn's test when a significant difference is found. Sample size estimation - Assuming that AIH has a modest treatment effect size of 0.6 compared to the Normoxia control group, with type I error set at 0.05 and type II error at 0.80, appropriately 20 subjects are needed in each group to provide sufficient power for the study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Peripheral Nerve Injuries

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    This study will investigate AIH's potential to condition and promote enhanced repair in a Phase I randomized control trial (RCT) of carpal tunnel syndrome (CTS) associated with severe median nerve compression/injury. We predict AIH will have better outcomes than current ES strategies and we aim to non-invasively condition/prime the IRP in compressed nerves by AIH treatment prior to nerve decompression and/or post-nerve decompression.
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    80 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Acute Intermittent Hypoxia
    Arm Type
    Active Comparator
    Arm Description
    Patients with hand weakness and numbness secondary to median nerve entrapment and scheduled for carpal tunnel release surgery will be randomly assigned to receive acute intermittent hypoxia
    Arm Title
    Normoxia control
    Arm Type
    Placebo Comparator
    Arm Description
    Patients with hand weakness and numbness secondary to median nerve entrapment and scheduled for carpal tunnel release surgery will be randomly assigned to receive normoxia
    Intervention Type
    Device
    Intervention Name(s)
    Acute Intermittent Hypoxia
    Intervention Description
    The acute intermittent hypoxia protocol will consist of 15 cycles of 1.5 min of inspiring ambient air (21% O2) alternating with 1.5 min of hypoxic air (9% O2)
    Intervention Type
    Device
    Intervention Name(s)
    Normoxia
    Intervention Description
    The normoxia protocol will consist of 15 cycles of 3 min of inspiring ambient air (21% O2)
    Primary Outcome Measure Information:
    Title
    Motor unit number estimation
    Description
    The number of motor units in the median innervated thenar muscles.
    Time Frame
    At 3, 6 and 12 months compared to baseline
    Secondary Outcome Measure Information:
    Title
    Two point discrimination
    Description
    Testing the A-beta sensory fibers using the Dellon-MacKinnon Disk
    Time Frame
    At 3, 6 and 12 months compared to baseline
    Title
    Fine touch sensation
    Description
    Testing the A-beta fibers using Semmes-Weinstein monofilaments
    Time Frame
    At 3, 6 and 12 months compared to baseline
    Title
    Quantitative sensory testing
    Description
    Cold threshold (A-beta fibers) and pain threshold (C fibers) using CASE IV quantitative sensory testing equipment
    Time Frame
    At 3, 6 and 12 months compared to baseline
    Title
    Boston Carpal Tunnel Symptom Severity
    Description
    Self administered questionnaire
    Time Frame
    At 3, 6 and 12 months compared to baseline
    Title
    Moberg Pick-up Test
    Description
    To measure hand dexterity and functional performance
    Time Frame
    At 3, 6 and 12 months compared to baseline

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: i) sensory impairments including numbness and pain; ii) nocturnal awakening by these symptoms; iii) weakness and wasting of the thenar musculature and, iv) loss of hand dexterity. v) Motor unit loss greater than 2 SD below the mean for the age group Exclusion Criteria: i) Chronic lung or cardiac disease ii) Other nerve disorders, previous carpal tunnel release or systemic illness including diabetes

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Non-invasive Therapy to Drive Nerve Regeneration

    We'll reach out to this number within 24 hrs